4 results match your criteria: "Japan. Electronic address: hayashij1949@haradoi-hospital.com.[Affiliation]"
Comparison of the effectiveness of core genome multilocus sequence typing and polymerase chain reaction-based open reading frame typing in tracing nosocomial methicillin-resistant Staphylococcus aureus transmission.
J Infect Chemother
January 2025
Department of Laboratory Medicine, Nagasaki University Graduate School of Biomedical Sciences, 1-7-1 Sakamoto, Nagasaki, 852-8501, Japan. Electronic address:
Article Synopsis
- - A shift in MRSA types has been noted in Japan, specifically from SCCmec type II/ST5 to SCCmec type IV/CC1, particularly in long-term care wards, raising concerns about unintentional MRSA transmission between patients and healthcare providers.
- - Researchers examined 83 MRSA isolates using polymerase chain reaction (POT) and core genome multilocus sequence typing (cgMLST), discovering that SCCmec type IV/CC1 was the most common, but cgMLST revealed fewer instances of nosocomial transmission than POT.
- - The study concluded that cgMLST is a more reliable method for detecting MRSA transmission in healthcare environments, emphasizing its importance in managing and preventing the spread of MR
Prevalence and characteristics of occult hepatitis B virus infection in Japanese human immunodeficiency virus-infected patients.
J Infect Chemother
January 2020
Kyushu General Medicine Center, Haradoi Hospital, 6-40-8 Aoba, Higashi-ku, Fukuoka, 813-8588, Japan. Electronic address:
Occult hepatitis B virus (HBV) infection (OBI) is hepatitis B surface antigen (HBsAg) negative but with detectable HBV DNA. Although HIV infection has been reported to be a risk factor for OBI, the prevalence and clinical features of OBI in Japanese HIV infected patients have not been documented. This retrospective, single-center study was conducted to determine the prevalence and characteristic of OBI in Japanese antiretroviral therapy (ART) naïve HIV infected patients.
View Article and Find Full Text PDFElbasvir plus grazoprevir for patients with chronic hepatitis C genotype 1: A multicenter, real-world cohort study focusing on chronic kidney disease.
Antiviral Res
November 2018
Kyushu General Internal Medicine Center, Haradoi Hospital, Fukuoka, Japan. Electronic address:
The real-world effectiveness and safety of all-oral direct-acting antivirals (DAAs) for chronic hepatitis C (HCV) infection and chronic kidney disease (CKD) have not been fully elucidated. This study assesses elbasvir (EBR) plus grazoprevir (GZR) for patients with HCV genotype 1 infection in the clinical setting, focusing on CKD stage 3-5D. This multicenter, real-world cohort study consisted of 282 Japanese patients who were treated with EBR (50 mg) plus GZR (100 mg) for a fixed 12-week duration.
View Article and Find Full Text PDFEffectiveness and safety of sofosbuvir plus ribavirin for HCV genotype 2 patients 65 and over with or without cirrhosis.
Antiviral Res
December 2016
Kyushu General Internal Medicine Center, Haradoi Hospital, Fukuoka, Japan. Electronic address:
Older patients with chronic hepatitis C virus (HCV) infection have historically been designated difficult-to-treat. We evaluated the efficacy and safety of sofosbuvir (nucleotide NS5B polymerase inhibitor) plus ribavirin for patients with HCV genotype 2 infection in a real-world clinical setting, with the focus on elderly patients aged ≥ 65. This large, multicenter study consisted of 446 Japanese HCV genotype 2 patients (303 treatment-naïve and 143 treatment-experienced), including 190 (42.
View Article and Find Full Text PDF